The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "rituximab"

Search results for: rituximab

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

November 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: Cancer, non-Hodgkin’s lymphoma, psoriatic arthritis, rituximab, rituximab-abbs, upadacitinib

FDA Approves Rituximab for Children with GPA & MPA

October 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

Intravenous rituximab can now be used to treat pediatric patients with GPA and MPA as young as two years old…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: giant cell arteritis (GCA), GPA, microscopic polyangiitis (MPA), rituximab, Vasculitis

Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases

September 2, 2019 • By Lara C. Pullen, PhD

Recent research into rituximab-induced serum sickness (RISS) reinforces the understanding that patients generally recover quickly. However, the study also found patients with autoimmune disease, especially SLE, had a significantly higher risk for developing RISS than patients using rituximab to treat hematological malignancy…... [Read More]

Filed Under: Conditions Tagged With: rituximab, rituximab-induced serum sickness, systemic lupus erythematosus (SLE)

Coding Corner Question: How to Bill a Rituximab Infusion Visit?

April 16, 2019 • By From the College

A 66-year-old female patient returns for a second infusion of rituximab for her diagnosis of rheumatoid arthritis in multiple sites. She is rheumatoid factor positive. She says the pain in her knees, elbows and neck has slightly improved. She rates the severity of her pain at a 7 on a 10-point scale, which is an… [Read More]

Filed Under: Billing/Coding, From the College, Rheumatoid Arthritis Tagged With: Infusion, rituximab

Coding Corner Answer: How to Bill a Rituximab Infusion Visit?

April 16, 2019 • By From the College

Take the challenge. CPT Codes: 96413, 96415 x 3, J9312 x 5, 96375, J2920 Diagnoses: M05.79 Coding Rationale As of Jan. 1, 2019, the Healthcare Common Procedure Coding System (HCPCS) code for rituximab was changed from J9310 rituximab 100 mg, to the new HCPCS code J9312 (injection, rituximab, 100 mg). According to a Verywell Health… [Read More]

Filed Under: Billing/Coding, From the College, Rheumatoid Arthritis Tagged With: Infusion, rituximab

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

January 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: biosimilar, FDA, filgotinib, Rheumatoid Arthritis (RA), rituximab, rituximab-abbs, U.S. Food and Drug Administration (FDA)

AAV Remission Study: Does Rituximab or Azathioprine Work Best?

December 17, 2018 • By Thomas R. Collins

Researchers sought to identify predictors of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) who took rituximab for maintenance had a better sustained remission rate through 60 months than those taking azathioprine, according to the latest results from the maintenance of remission using rituximab in systemic ANCA-associated vasculitis (MAINRITSAN) trial, a prospective, randomized trial… [Read More]

Filed Under: Research Reviews, Vasculitis Tagged With: ANCA-Associated Vasculitis, azathioprine, MAINRITSAN, maintenance, rituximab

Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

December 17, 2018 • By Kurt Ullman

Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The… [Read More]

Filed Under: Research Reviews, Vasculitis Tagged With: ANCA-Associated Vasculitis, MAINRITSAN2, maintenance, rituximab

Rituximab Receives Label Update for ANCA-Associated Vasculitis

November 26, 2018 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: FDA, GPA, granulomatosis with polyangiitis, microscopic polyangiitis (MPA), U.S. Food and Drug Administration (FDA)

Trimethoprim-Sulfamethoxazole Prophylaxis Reduced Rituximab Infection Risk

October 18, 2018 • By Kathy Holliman

Severe infections occurred in 25% of patients with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) who were treated with rituximab, according to results of an observational study conducted in the United Kingdom (U.K.) and Austria. Trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, however, reduced the risk of severe infections, the investigators reported in Annals of the Rheumatic Diseases.1 Andreas… [Read More]

Filed Under: Conditions, Drug Updates, Vasculitis Tagged With: antibody-associated vasculitis, Infection, rituximab

  • 1
  • 2
  • 3
  • …
  • 25
  • Next Page »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.